|
104
|
357
|
11zlA |
Crystal structure of human jnk1 kinase domain in complex with inhibitor ccd-3013 |
|
104
|
358
|
12cvA |
Crystal structure of human jnk1 kinase domain in complex with inhibitor ccd-2728 |
|
81
|
287
|
13lwA |
Structure of pkmyt1 bound to inhibitor p32-(s) |
|
79
|
291
|
13lxA |
Structure of pkmyt1 bound to inhibitor p32-(r) |
|
83
|
289
|
13lvA |
Structure of pkmyt1 bound to allosteric inhibitor p29-(s) |
|
104
|
349
|
9ylhA |
Human p38 alpha mapk:mw01-8-105srm n,n-dimethyl-6-phenyl-5-(4-pyridinyl)-3-pyridazinamine inhibitor complex |
|
88
|
295
|
9psuA |
Irak4 in complex with compound 12 |
|
95
|
294
|
9pstA |
Irak4 in complex with compound 5 |
|
92
|
295
|
9pssA |
Irak4 in complex with compound 3 |
|
107
|
342
|
9o7qA |
Crystal structure of human adenosine kinase (adk) in complex with inhibitor bki-1676 |
|
104
|
342
|
9o7pA |
Crystal structure of human adenosine kinase (adk) in complex with inhibitor bki-1817 |
|
103
|
342
|
9o7rA |
Crystal structure of human adenosine kinase (adk) in complex with inhibitor bki-1553 |
|
109
|
323
|
9zkgA |
Vrk1 in complex with the inhibitor mp-60 |
|
84
|
270
|
9zlmA |
Crystal structure of btk kinase domain bound to compound ys2 |
|
89
|
268
|
9zljA |
Crystal structure of btk kinase domain bound to compound ys1 |
|
205
|
625
|
9py1A |
Prmt5 bound to compound 8 and mta |
|
103
|
297
|
9z28A |
Khk bound to compound 7 |
|
102
|
297
|
9z2bA |
Khk bound to compound 18 |
|
201
|
625
|
9pxzA |
Prmt5 bound to compound 6 and mta |
|
211
|
625
|
9py0A |
Prmt5 bound to compound 12 and mta |
|
101
|
297
|
9z29A |
Khk bound to compound 9 |
|
104
|
296
|
9z2cA |
Khk bound to gs-1291269 |
|
75
|
308
|
9py1B |
Prmt5 bound to compound 8 and mta |
|
71
|
308
|
9pxzB |
Prmt5 bound to compound 6 and mta |
|
103
|
298
|
9z2aA |
Khk bound to compound 12 |
|
74
|
308
|
9py0B |
Prmt5 bound to compound 12 and mta |
|
83
|
273
|
9nd3A |
Jak2 pseudokinase domain in complex with diaminotriazole inhibitor |
|
77
|
274
|
9nd5A |
Jak2 pseudokinase domain in complex with diaminotriazole covalent inhibitor |
|
48
|
220
|
9cvdA |
Set domain of histone-lysine n-methyltransferase nsd2 in complex with selective inhibitor |
|
180
|
468
|
9c0pA |
M. tuberculosis pks13 acyltransferase (at) domain in complex with sufex inhibitor cec215 |
|
99
|
318
|
9dn3A |
Crystal structure of human inositol 1,3,4-trisphosphate 5/6-kinase (itpk1) in complex with an inhibitor 9-cylcopentyladenine |
|
111
|
304
|
8vw4A |
Crystal structure of cbl-b tkb bound to compound 26 |
|
111
|
304
|
8vw5B |
Crystal structure of cbl-b tkb bound to compound 2 |
|
110
|
304
|
8vw5A |
Crystal structure of cbl-b tkb bound to compound 2 |
|
108
|
348
|
9di9A |
Rat branched chain ketoacid dehydrogenase kinase in complex with inhibitor |
|
90
|
300
|
9cd5A |
Fgfr1 kinase domain soak with inhibitor tyra-300 |
|
88
|
305
|
9cd7A |
Fgfr3 kinase domain with inhibitor tyra-300 |
|
69
|
309
|
9c10B |
Amg 193, a clinical stage mta-cooperative prmt5 inhibitor, drives anti-tumor activity preclinically and in patients with mtap-deleted cancers |
|
190
|
625
|
9c10A |
Amg 193, a clinical stage mta-cooperative prmt5 inhibitor, drives anti-tumor activity preclinically and in patients with mtap-deleted cancers |
|
180
|
700
|
9ay9A |
Co-crystal structure of human prmt9 in complex with mrk-990 inhibitor |
|
109
|
318
|
8uoiA |
Crystal structure of human nuak1-mark3 kinase domain chimera bound with small molecule inhibitor #65 |
|
108
|
327
|
8uohA |
Crystal structure of human nuak1-mark3 kinase domain chimera bound with small molecule inhibitor #10 |
|
115
|
321
|
8uojA |
Crystal structure of human nuak1-mark3 kinase domain chimera bound with azepane (r)-#50 small molecule inhibitor |
|
105
|
320
|
8uolA |
Crystal structure of human nuak1-mark3 (6 mutations) kinase domain chimera bound with small molecule inhibitor #31 |
|
112
|
319
|
8uokA |
Crystal structure of human nuak1-mark3 (7 mutations) kinase domain chimera bound with small molecule inhibitor #31 |
|
110
|
350
|
8yd9A |
Crystal structure of p38alpha with an allosteric inhibitor 3 |
|
83
|
327
|
8xb1A |
Crystal structure of flt3 in complex with a pyrazinamide macrocycle derivative |
|
90
|
298
|
8w38A |
Tas-120 covalent structure with fgfr2 molecular brake mutant |
|
96
|
298
|
8w3dA |
Tas-120 covalent structure with fgfr2 molecular brake mutant |
|
89
|
314
|
8w2xA |
Tas-120 covalent structure with fgfr2 |
